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RNA-amino acid and RNA-peptide conjugates that mimic charged tRNA 30-ends are valuable substrates
for structural and functional investigations of ribosomal complexes. To obtain such conjugates, most syn-
thetic approaches that are found in the literature make use of puromycin. This well available aminonu-
cleoside antibiotic contains a dimethylamino group at the nucleobase and a methylated tyrosine that is
connected via an amide linkage to the ribose moiety. To increase structural diversity, we present the syn-
thesis of a N6,N6-dimethylated 30-azido-30-deoxyadenosine precursor that can be coupled to any amino
acid. Further derivatization results in the solid support that is eligible for the preparation of stable 30-ami-
noacyl- or 30-peptidyl-tRNA termini with an amide instead of the natural ester linkage. The present work
expands our previously established route that delivered a broad range of peptidyl-tRNA mimics to the
corresponding counterparts with N6,N6-dimethylation pattern of the terminal adenosine (A76). This
aspect is of signiﬁcance to modulate the binding preferences of the mimics for ribosomal A- versus P-site.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).cyl-tRNA
thylation1. Introduction
High-resolution structures of the ribosome and its complexes
with protein factors have become an indispensible basis to
understand the intriguing functions of this cellular apparatus.1–5
They deliver fundamental insights through snapshots along the
mechanistic road map of ribosome function and facilitate the
design of genetic and biochemical experiments due to the knowl-
edge of the three-dimensional positioning of the functional groups
of interest.
For many X-ray crystallographic or cryo-electron-microscopic
approaches, ribosome assembly with peptidyl- or aminoacyl-tRNA
is needed. Such efforts can be severely hindered because of the eas-
ily hydrolyzable ester group that results in cleavage of the peptide
moiety from the tRNA.6 These limitations, however, can be over-
come by a stable linkage, for instance by 30-amide-linked amino-
acyl- or peptidyl-tRNA mimics that represent analogues to the
naturally occurring antibiotic puromycin (Pmn) (Fig. 1).6–8 Such
conjugates possess the propensity of higher stability during ribo-
some/tRNA assembly procedures, and at the same time, prevent
ribose 20-O/30-O transesteriﬁcation or transpeptidation. They are
of immediate interest for the structural characterization of the
diverse functional states passed through during the ribosomalelongation cycle and phenomena related thereto,9–20 where mim-
ics can be useful for A- and/or P-site substrate occupation. More
recently, conjugates of that kind have been applied to elucidate
peptide-mediated macrolide antibiotic resistance and ribosome
stalling,21 and for investigations of selenocysteine biosynthesis.22
The synthesis of 30-aminoacyl- and 30-peptidyl-RNA conjugates
is challenging and often represents a serious hurdle. Therefore, we
and others have put signiﬁcant efforts into novel synthetic strate-
gies that rely on 30-aminoacylamino-30-deoxyadenosine modiﬁed
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thesis.23–27 More recent developments from our group have
expanded the procedures to allow for site-speciﬁc methylation,
phosphorylation and phosphonation of the RNA-peptide conju-
gates,22 and beyond that, use native chemical ligation to increase
amino acid side chain ﬂexibility.28,29 All of our approaches so far
pass a 30-azido-30-deoxyadenosine derivative as key intermediate,
as originally shown in 2009.26 This intermediate allows to couple
structurally diverse amino acids at a late stage of the synthesis,
representing a signiﬁcant advantage over most other synthetic
strategies that make use of puromycin as key precursor,11,30
thereby accepting the drawback that the amino acid at the junction
is restricted to O-methylated tyrosine.
Another difference to puromycin derived tRNAmimics accounts
for the dimethylation pattern at the exocyclic amino group of ade-
nine. This methylation pattern has been discussed to inﬂuence A-
versus P-site binding speciﬁcity of short CCA/CCPmn substrates.31
Unfortunately, efﬁcient routes to obtain RNA conjugates with a ter-
minal 30-amino-30-deoxy-N6,N6-dimethyladenosine and with ﬂexi-
bility concerning the nature of the connected amino acid are still
lacking. The synthesis of this type of conjugates currently relies
on the hydrolysis of puromycin which is cost-intensive and limited
in terms of quantities.32 We therefore set out to create an alterna-
tive and convenient approach, exempliﬁed here by the syntheses of
the hydrolysis-resistant ACC(m62A)-Gly and ACC(m62A)-Lys(N6,N6,
N6-(CH3)3) tRNA mimics.
2. Results and discussion
The starting point for our undertakingwas 9-(30-azido-30-deoxy-
b-D-arabinofuranosyl)adenine1 (Scheme1),whichwas synthesized
in two steps from commercially available 9-(arabinofuranosyl)Scheme 1. Synthesis of the modiﬁed solid supports 8 and 10. Reaction conditions: (a) 3.5
2.5 equiv Et3SiCl in pyridine, reﬂux, 24 h; (b) 40% aqueous dimethylamine, in pyridine,
1.6 equiv triﬂuoromethanesulfonyl chloride, 1.6 equiv DMAP, 2.8 equiv (iPr)2NEt in CH
(iPr)2NEt in toluene, 16 h, 80 C, 81%; (e) i. H2/Pd, ethyl acetate, 22 h, rt, 92%, ii. 1.3 equiv F
27%; (f) 3 equiv or 2 equiv of adipic acid bis(pentaﬂuorophenyl)ester for 6 and 9 respecti
(9awas used without isolation in the next step); (g) 1 equiv amino-functionalized polys
dimethylformamide, rt, 1 day, loading: 45 lmol/g for 8 and 18 lmol/g for 10.
Pfp = pentaﬂuorophenyl.adenine based on a published procedure.33 Treatment of 1 with
N,N0-bis[(dimethylamino)methylene]-hydrazine (BDMAMH) dihy-
drochloride34,35 and TESCl in pyridine gave 9-(3-azido-3-deoxy-b-
D-arabinofuranosyl)-6-(1,2,4-triazol-4-yl)purine 2, which was
converted quantitatively into 9-(3-azido-3-deoxy-b-D-arabinofur-
anosyl)-6-(dimethylamino)purine 3 with aqueous dimethylamine.
Then, derivative 3 was transformed into the dimethoxytritylated
compound4. Triﬂation of the arabinose20-OH resulted in intermedi-
ate 4a, which was converted into the ribonucleoside 5 in diastereo-
selective manner by treatment with potassium triﬂuoroacetate and
18-crown-6-ether. Subsequently, Pd/C-catalyzed hydrogenation
provided 9-(3-amino-3-deoxy-b-D-ribo-furanosyl)-6-(dimethyl-
amino)purine 5a as intermediate. Coupling with Fmoc-protected
glycine furnished the amino acid linked building blocks 6, which
was further transformed into the pentaﬂuorophenyl active ester 7
using adipic acid bis(pentaﬂuorophenyl)ester8 as tether. Coupling
of compound 7 to amino-modiﬁed polystyrene (GE Healthcare,
Custom Primer Support™ 200 Amino) ﬁnally yielded the desired
30-aminoacylamino-30-deoxy-N6,N6-dimethyladenosine-function-
alized solid support 8 (Scheme 1). To demonstrate the versatility of
the approach we applied N6,N6,N6-trimethyl-L-lysine instead of
glycine and obtained the corresponding solid support 10.
In principle, solid supports 8 and 10 can be utilized for elonga-
tion of a peptide by automated solid-phase peptide synthesis based
on N-(9-ﬂuorenyl)methoxycarbonyl (Fmoc) protected amino acids,
as we have shown previously on the analogous 30-aminoacylamino-
30-deoxyadenosine-functionalized solid support series.22,26,36 Here,
the support 8was manually coupled with the corresponding Fmoc-
protected amino acid using the tetramethyl-O-(1H-benzotriazol-1-
yl)uronium (HBTU) reagent. Subsequently, solid supports 8 and 10
were directly supplied to solid phase RNA synthesis. Oligoribonu-
cleotide assembly was based on 20-O-[(triisopropylsilyl)oxy]methylequiv N,N0-bis[(dimethylamino)methylene]-hydrazine (BDMAMH) dihydrochloride,
rt, 1 h, (72%, over (a) and (b)); (c) 1.2 equiv DMT-Cl, in pyridine, 16 h, rt, 93%; (d) i.
2Cl2, 30 min, 0 C, 84%, ii. 5.5 equiv CF3COOK+, 2.0 equiv 18-crown-6, 2.5 equiv
moc-Gly-OPfp in DMF, rt, 5 h, 95% or 1.5 equiv Fmoc-Lys(CH3)3-OBt in DMF, rt, 12 h,
vely, 1 equiv DMAP in N,N-dimethylformamide/pyridine (1/1, v/v), rt, 1 h, 51% for 7,
tyrene support (GE Healthcare, Custom Primer Support™ 200 Amino), pyridine, N,N-
DMAP = 4-(N,N-dimethylamino)pyridine, Fmoc = N-(9-ﬂuorenyl)methoxycarbonyl,
Figure 2. Synthesis of RNA-peptide conjugates based on the modiﬁed solid
supports 8 and 10. Anion-exchange HPLC proﬁles of crude and puriﬁed (insets)
conjugates S1 and S3 (A,B; upper panels) and LC-ESI mass spectra of puriﬁed
products (A,B; lower panels). Anion-exchange chromatography conditions: Dionex
DNAPacPA-100 (4  250 mm) column; temperature: 60 C; ﬂow rate: 1 mL/min;
eluant A: 25 mM TrisHCl (pH 8.0), 6 M urea; eluant B: 25 mM TrisHCl (pH 8.0), 6 M
urea, 500 mM NaClO4; gradient: 0–40% B in A within 25 min; UV detection at
260 nm.
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performed on an oligonucleotide synthesizer following standard
protocols. The introduction of the 50-phosphate group at the
50-end of RNA-peptide conjugates was accomplished as ﬁnal cycle
of the automated solid-phase synthesis by using a modiﬁed phos-
phoramidite building block prepared according to the literature.39
The solid supports were treated with diethylamine in acetoni-
trile to eliminate the cyanoethyl and Fmoc protecting groups.
The conjugates were then cleaved from the solid support using
aqueous ammonia in ethanol under concomitant cleavage of the
remaining acetyl protecting groups. Subsequent treatment with
1.0 M tetrabutylammonium ﬂuoride trihydrate (TBAF3H2O) in
tetrahydrofuran at 37 C overnight liberated the 20-OH groups. This
procedure resulted in high quality crude products which were
analyzed by anion-exchange HPLC. The major peak of the HPLC
proﬁles typically represented the desired conjugate which was
puriﬁed on a semi-preparative column to achieve purities of more
than 95%. Finally, the integrity of the products was analyzed by LC-
ESI mass spectrometry and conﬁrmed the expected molecular
weights (Fig. 2). Following this approach, we prepared the short
aminoacyl-RNA and dipeptide-RNA conjugates listed in Table 1.Table 1
Selection of synthesized RNA-peptide conjugates
No Sequencea Amount
(nmol)
m.w.calcd
(amu)
m.w.found
(amu)
S1 50-p-ACC(m62A-30-NH)-Gly 420 1370.27 1370.69
S2 50-p-GCACC(m62A-30-NH)-Gly 260 2021.31 2021.27
S3 50-p-ACC(m62A-30-NH)-Lys(CH3)3 130 1485.13 1483.92
S4 50-p-ACC(m62A-30NH)-Gly-Phe 600 1518.10 1517.92
S5 50-pGCACC(m62A-30NH)-Gly-Phe 620 2168.49 2168.43
a For chemical structure of the nucleoside junction see Figure 1.3. Conclusion
In this study, we have presented the efﬁcient synthesis of the
functionalized solid supports 8 and 10 for solid-phase synthesis
of hydrolysis-resistant 30-peptidyl-tRNA conjugates with puromy-
cin-like N6,N6-dimethyladenosine pattern at the nucleoside junc-
tion. The novel aspects compared to our previous work and to
work by others who use puromycin as tether, are given by the syn-
thetic ﬂexibility concerning the nature of the amino acid attached
to the dimethylated adenosine and its convenient access from
9-(30-azido-30-deoxy-b-D-arabinofuranosyl)purine 1 in large quan-
tities. Therefore, we signiﬁcantly expand the scope of applications
of these conjugates which are required to explore mechanistic
details of ribosomal translation.9 In particular, these derivatives
are promising to modulate the binding preferences of the mimics
for ribosomal A- versus P-site in crystallographic studies.4. Experimental
4.1. Solid support synthesis
4.1.1. General remarks
Reagents were purchased in the highest available quality from
commercial suppliers (Sigma–Aldrich, Acros, IRIS Biotech GmbH)
and used without further puriﬁcation. Organic solvents for reac-
tions were dried overnight over freshly activated molecular sieves
(4 Å). The reactions were carried out under argon atmosphere. 1H
and 13C spectra were recorded on a Bruker DRX 300 MHz spectrom-
eter. Chemical shifts (d) are reported relative to tetramethylsilane
(TMS) referenced to the residual proton signal of the deuterated sol-
vent DMSO-d6 (2.50 ppm for 1H NMR spectra and 39.52 ppm for 13C
spectra). The following abbreviations were used to denote multi-
plicities: s = singlet, d = doublet, t = triplet, m = multiplet, b = broad.
Signal assignments are based on 1H-1H-COSY and 1H-13C-HSQC
experiments. MS experiments were performed on a Finnigan LCQ
AdvantageMAX ion trap instrumentation (Thermo Fisher Scientiﬁc)
with an electrospray ion source. Samples were analyzed in the posi-
tive- or negative-ion mode. Reaction control was performed via
analytical thin-layer chromatography (TLC, Macherey-Nagel) with
ﬂuorescent indicator. Spots were further visualized using cerium
molybdate or anisaldehyde staining reagents. Column chromatog-
raphy was carried out on silica gel 60 (70–230 mesh). Custom
Primer Support™ 200 Amino was purchased from GE Healthcare.
Fmoc-L-Lys(Me3)-OH*Cl was purchased from Iris Biotech GmbH.
4.1.2. 9-(30-Azido-30-deoxy-b-D-arabinofuranosyl)-6-(1,2,4-
triazol-4-yl)purine (2)
9-(30-Azido-30-deoxy-b-D-arabinofuranosyl)purine 1 (2.41 g,
8.25 mmol) and N,N-dimethylformamide azine dihydrochloride
(6.20 g, 28.84 mmol) were dried over phosphorus pentoxide under
high vaccum for 30 min and then suspended in 50 mL of dry
pyridine. Chlorotriethylsilane (3.50 mL, 20.9 mmol) was added
via syringe and the reaction mixture was reﬂuxed for 24 h. All
volatiles were evaporated under reduced pressure and the
reddish-brown residue was dissolved in 200 mL of cold dichloro-
methane, washed with 200 mL of a cold 1:2 mixture of saturated
sodium bicarbonate solution and brine and subsequently with
200 mL of a cold 1:2 mixture of 2 M HCl and brine. The organic
phase was dried over Na2SO4 and evaporated. The resulting brown
oil was dissolved in methanol (70 mL) and treated with 5.5 mL of
2 M aqueous HCl in portions until deprotection was deemed com-
plete by TLC. All volatiles were evaporated in vacuo. Crude com-
pound 2 can be puriﬁed by column chromatography on silica gel
with 1–5% methanol in dichloromethane, or directly used in the
next step. TLC (10% methanol in dichloromethane): Rf = 0.22. 1H
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H(b)-C(50)), 3.86–3.89 (m, 1H, H-C(40)), 4.42 (t, J = 8.5 Hz, 1H,
H-C(30)), 4.68 (m, 1H, H-C(20)), 5.32–5.35 (m, 1H, HO-C(50)), 6.21
(d, J = 5.8 Hz, 1H, HO-C(20)), 6.48 (d, J = 6.4 Hz, H-C(10)), 8.94 (s,
1H, H-C(2) or H-C(8)), 8.99 (s, 1H, H-C(2) or H-C(8)), 9.65 (s, 2H,
H-C(3)triazole and H-C(5)triazole) ppm. 13C NMR (75 MHz, DMSO-
d6): d 60.00 (C(50)), 63.56 (C(30)), 74.53 (C(20)), 80.39 (C(40)),
83.06 (C(10)), 140.90 (C(3)triazole and C(5)triazole), 146.50 (C(2) or
C(8)); 152.00 (C(2) or C(8)) ppm. ESI-MS (m/z): [M+H+Et3N]+ calcd
for C12H12N10O3, 446.23; found 446.00.
4.1.3. 9-(30-Azido-30-deoxy-b-D-arabinofuranosyl)-6-
(dimethylamino)purine (3)
Crude compound 2 from the previous reaction was dissolved in
40% aqueous dimethylamine (60 mL, 474 mmol) and 40 mL of pyr-
idine and was stirred vigorously at room temperature for one hour,
after which the substitution was judged complete by TLC. All vol-
atiles were evaporated and the residue was puriﬁed by column
chromatography on silica gel with 1–5% methanol in dichloro-
methane. Yield over two steps: 1.89 g of (3) as white solid (72%).
TLC (10% methanol in dichloromethane): Rf = 0.50. 1H NMR
(300 MHz, DMSO-d6): d 3.45 (s, 6H, C(6)-N(CH3)2), 3.61–3.72 (m,
2H, H(a)-C(50), H(b)-C(50)), 3.76–3.81 (m, 1H, H-C(40)), 4.34 (t,
J = 8.1 Hz, 1H, H-C(30)), 4.45 (q, J = 6.7 Hz, 1H, H-C(20)), 5.27 (m,
1H, HO-C(50)), 6.07 (d, J = 5.8 Hz, 1H, HO-C(20)), 6.28 (d, J = 6.4 Hz,
1H, H-C(10)), 8.21 (s, 1H, H-C(2) or H-C(8)), 8.29 (s, 1H, H-C(2) or
H-C(8)) ppm. 13C NMR (75 MHz, DMSO-d6): d 37.91 (C(6)-N(CH3)
2), 60.19 (C(50)), 64.02 (C(30)), 74.71 (C(20)), 79.88 (C(40)), 82.21
(C(10)), 138.87 (C(2) or C(8)), 150.39 (C(2) or C(8)) ppm. ESI-MS
(m/z): [M+H+Et3N]+ calcd for C12H16N8O3, 321.14; found 321.05.
4.1.4. 9-[30-Azido-30-deoxy-50-O-(4,40-dimethoxytrityl)-b-D-
arabinofuranosyl]-6-(dimethylamino)purine (4)
Compound 3 (413 mg, 1.29 mmol) was dried over potassium
hydroxide under high vacuum for 30 min and suspended in
5.5 mL of dry pyridine. 4,40-Dimethoxytrityl chloride (524 mg,
1.55 mmol) was added in one portion and the yellow solution
was stirred for 3.5 h. The reaction was quenched with 5 mL of
methanol and volatiles were evaporated. The yellow residue was
partitioned between 50 mL of ethyl acetate and 30 mL of 5% aque-
ous citric acid and the organic layer was washed with 5% aqueous
citric acid, saturated sodium bicarbonate and brine (30 mL each).
The organic phase was dried over MgSO4 and evaporated to pro-
vide a yellow foam. The product was puriﬁed by column chroma-
tography on silica gel with 10% n-hexane in ethyl acetate, and
subsequently, with neat ethyl acetate. Yield: 748 mg of 4 as white
foam (93%). TLC (ethyl acetate): Rf = 0.44. 1H NMR (300 MHz,
DMSO-d6): d 3.23–3.36 (m, 2H, H(a)-C(50), H(b)-C(50)), 3.46 (s, 6H,
C(6)-N(CH3)2), 3.72 (s, 6H, 2  O-CH3(DMT)), 3.92 (m, 1H, H-
C(40)), 4.46 (t, 1H, H-C(30)), 4.54–4.58 (m, 1H, H-C(20)), 6.14 (d,
1H, HO-C(20)), 6.32 (d, 1H, H-C(10)), 6.81–6.86 (t, 4H, H-C(ar)),
7.18–7.29 (m, 7H, H-C(ar)), 7.37 (d, 2H, H-C(ar)), 8.17 (s, 1H,
H-C(2) or H-C(8)), 8.19 (s, 1H, H-C(2) or H-C(8)) ppm. 13C NMR
(75 MHz, DMSO-d6): d 37.88 (C(6)-N(CH3) 2), 54.97 (2  O-CH3
(DMT)), 63.40 (C(50)), 64.98 (C(30)), 74.11 (C(20)), 78.18 (C(40)),
82.15 (C(10)), 113.15 (C(ar)), 118.85, 126.70 (C(ar)), 127.65
(C(ar)), 127.79 (C(ar)), 129.63 (C(ar)), 129.71 (C(ar)), 135.28,
135.36, 139.05 (C(2) or C(8)), 144.68, 150.38, 151.84, 154.20
(C(2) or C(8)), 158.06, 158.10 ppm. ESI-MS (m/z): [M+H]+ calcd
for C33H34N8O5, 623.27; found 623.22.
4.1.5. 9-[30-Azido-30-deoxy-20-O-(triﬂuoromethanesulfonyl)-50-
O-(4,40-dimethoxytrityl)-b-D-arabinofuranosyl]-6-
(dimethylamino)purine (4a)
Compound 4 (650 mg, 1.04 mmol) and 4-(dimethylamino)pyri-
dine (205 mg, 1.68 mmol) were weighed into an oven dried ﬂaskcontaining a magnetic stirring bar and were dried over potassium
hydroxide under high vacuum for one hour. A rubber septum was
then attached under argon and 17 mL of dry dichloromethane and
N,N-diisopropylethylamine (490 lL, 2.81 mmol) were added. The
ﬂask was cooled in an icebath and triﬂuoromethanesulfonyl chlo-
ride (180 lL, 1.69 mmol) from a freshly opened ampule was slowly
added. The reactionwas allowed to proceed for 1 h at 0 C and 2 h at
room temperature, after which the starting material was no longer
visible on TLC. The mixture was diluted with 75 mL of dichloro-
methane and washed with saturated sodium bicarbonate solution
and brine (75 mL each), dried over Na2SO4 and evaporated to pro-
vide a brown foam. Compound 4awas puriﬁed by silica gel column
chromatography using 25–50% ethyl acetate in n-hexane. Yield:
658 mg of 4a as white foam (84%). TLC (ethyl acetate/n-hexane
1:1): Rf = 0.50. 1H NMR (300 MHz, DMSO-d6): d 3.32–3.34 (m, 2H,
H(a)-C(50), H(b)-C(50)), 3.46 (s, 6H, C(6)-N(CH3)2), 3.72 (s, 6H,
2  O-CH3(DMT)), 4.19 (m, 1H, H-C(40)), 5.02 (t, 1H, H-C(30)), 5.67
(t, 1H, H-C(20)), 6.26 (d, 1H, H-C(10)), 6.80–6.85 (m, 4H, H-C(ar)),
7.20–7.28 (m, 7H, H-C(ar)), 7.35 (d, 2H, H-C(ar)), 8.18 (s, 1H,
H-C(2) or H-C(8)), 8.35 (s, 1H, H-C(2) or H-C(8)) ppm. ESI-MS
(m/z): [M+H]+ calcd for C34H33F3N8O7S, 755.22; found 755.19.4.1.6. 30-Azido-30-deoxy-50-O-(4,40-dimethoxytrityl)-6-N-
dimethyl-b-D-adenosine (5)
Triﬂate 4a (300 mg, 0.397 mmol), 18-crown-6 (210 mg,
0.794 mmol) and potassium triﬂuoroacetate (333 mg, 2.19 mmol)
were weighed into an oven dried ﬂask containing a magnetic stir-
ring bar and dried over potassium hydroxide under high vacuum
for one hour. 15 mL of dry toluene and N,N-diisopropylethylamine
(175 lL, 1.00 mmol) were added. The suspension was stirred for
6.5 h at 80 C, then all volatiles were evaporated. The residue was
partitioned between 50 mL of ethyl acetate and 50 mL of saturated
sodium bicarbonate solution and the aqueous layer extracted with
30 mL of ethyl acetate. The organic layers were washed with 50 mL
of brine, dried over MgSO4 and evaporated. Compound 5 was
puriﬁed by silica gel gradient column chromatography using
50–0% n-hexane in ethyl acetate. Yield: 200 mg of 5 as white foam
(81%). TLC (ethyl acetate/n-hexane 2:1): Rf = 0.25. 1H NMR
(300 MHz, DMSO-d6): d 3.19–3.28 (m, 2H, H(a)-C(50), H(b)-C(50)),
3.45 (s, 6H, C(6)-N(CH3)2), 3.72 (s, 6H, 2  O-CH3(DMT)), 4.12 (m,
1H, H-C(40)), 4.42 (t, 1H, H-C(30)), 5.07–5.12 (m, 1H, H-C(20)), 5.97
(d, 1H, H-C(10)), 6.33 (d, 1H, HO-C(20)), 6.80–6.85 (m, 4H, H-C(ar)),
7.19–7.29 (m, 7H, H-C(ar)), 7.34 (d, 2H, H-C(ar)), 8.18 (s, 1H,
H-C(2) or H-C(8)), 8.30 (s, 1H, H-C(2) or H-C(8)) ppm. 13C NMR
(75 MHz, DMSO-d6): d 37.93 (C(6)-N(CH3)2), 54.97 (2  O-CH3
(DMT)), 61.05 (C(30)), 63.23 (C(50)), 73.57 (C(20)), 80.03 (C(40)),
85.64, 88.16 (C(10)), 113.13 (C(ar)), 119.68, 126.68 (C(ar)), 127.63
(C(ar)), 127.78 (C(ar)), 129.61 (C(ar)), 129.70 (C(ar)), 135.31,
135.41, 138.48 (C(2) or C(8)), 144.71, 150.03, 151.96, 154.27 (C(2)
or C(8)), 158.04, 158.07 ppm. ESI-MS (m/z): [M+H]+ calcd for
C33H34N8O5, 623.27; found 623.25.4.1.7. 30-Amino-30-deoxy-50-O-(4,40-dimethoxytrityl)-N6,N6-
dimethyl-b-D-adenosine (5a)
Compound 5 (300 mg, 0.482 mmol) was dissolved in 15 mL of
ethyl acetate and palladium on activated charcoal (35 mg, 10% Pd,
33 lmol Pd) was added. The ﬂask was equipped with a rubber sep-
tum and ﬂushed with argon. Hydrogen was bubbled through the
stirred suspension for 15 min and then the reaction was held under
positive hydrogen pressure for 22 h. The suspension was ﬁltered
through a pad of celite and the solvent was evaporated to a white
foam of high purity. Product 5awas puriﬁed by column chromatog-
raphy on silica gel with 1–9% methanol in dichloromethane. Yield:
264 mg of 5a as white foam (92%). TLC (10% methanol in dichloro-
methane): Rf = 0.38. 1H NMR (300 MHz, DMSO-d6): d 1.58 (s, 2H,
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C(6)-N(CH3)2), 3.60–3.65 (m, 1H, H-C(30)), 3.72 (s, 6H, 2  O-CH3
(DMT)), 3.83–3.85 (m, 1H, H-C(40)), 4.39 (d, 1H, H-C(20)), 5.85 (s,
1H, HO-C(20)), 6.00 (d, 1H, H-C(10)), 6.78–6.83 (m, 4H, H-C(ar)),
7.16–7.26 (m, 7H, H-C(ar)), 7.35 (d, 2H, H-C(ar)), 8.23 (s, 1H,
H-C(2) or H-C(8)), 8.24 (s, 1H, H-C(2) or H-C(8)) ppm. 13C NMR
(75 MHz, DMSO-d6): d 37.88 (C(6)-N(CH3)2), 53.35 (C(30)), 54.94
(2  O-CH3 (DMT)), 63.78 (C(50)), 74.27 (C(20)), 83.25 (C(40)),
85.44, 89.31 (C(10)), 113.04, 119.63, 126.55, 127.70, 129.66,
129.74, 135.59, 135.65 (C(ar)), 137.86 (C(2) or C(8)), 144.94,
149.80, 151.90 (C(2) or C(8)), 154.24, 157.94, 157.98 ppm. ESI-MS
(m/z): [M+H]+ calcd for C33H36N6O5, 597.28; found 596.89.
4.1.8. 30-{[N-(9-Fluorenyl)methoxycarbonyl-glycyl]amino}-30-
deoxy-50-O-(4,40-dimethoxytrityl)-N6,N6-dimethyl-b-D-
adenosine (6)
Compound 5a (165 mg, 0.276 mmol) and N-(9-ﬂuore-
nyl)methoxycarbonyl glycine pentaﬂuorophenyl ester (165 mg,
0.356 mmol) were dried under high vacuum for 30 min. 2 mL of
dry DMF was then added and the solution was stirred for 5.5 h at
room temperature. The reaction mixture was diluted with 30 mL
of dichloromethane, washed with saturated sodium bicarbonate
solution and brine, dried over Na2SO4 and evaporated. Compound
6 was puriﬁed by silica gel column chromatography using 1–9%
methanol in dichloromethane as the eluent. Yield: 230 mg off-
white solid (95%). TLC (7% methanol in dichloromethane):
Rf = 0.27. 1H NMR (300 MHz, DMSO-d6): d 3.24 (bd, 2H, H(a)-C(50),
H(b)-C(50)), 3.46 (br s, 6H, C(6)-N(CH3)2), 3.70 (s, 8H, 2  O-CH3
(DMT), CH2 (a, Gly)), 4.14 (m, 1H, H-C(40)), 4.20–4.31 (m, 3H,
H-C(9, Fmoc)), OCH2 (Fmoc)), 4.64 (m, 1H, H-C(20)), 4.71–4.79
(m, 1H, H-C(30)), 6.01 (bd, 1H, H-C(10)), 6.10 (d, J = 4.6 Hz, 1H,
HO-C(20)), 6.79–6.84 (m, 4H, H-C(ar, DMT)), 7.19–7.34 (m, 12H,
H-C(ar)), 7.38–7.43 (m, 2H, H-C(ar)), 7.53 (t, J = 6.0 Hz, 1H,
NH(Gly)), 7.70–7.72 (m, 2H, H-C(ar)), 7.87–7.90 (m, 2H, H-C(ar)),
7.94 (d, J = 8.0 Hz, 1H, NH-C(30)), 8.21 (s, 1H, H-C(2) or H-C(8)),
8.27 (s, 1H, H-C(2) or H-C(8)) ppm. 13C NMR (75 MHz, DMSO-d6):
d 37.89 (C(6)-N(CH3)2), 43.30 (C(a, Gly)), 46.61 (C(9, Fmoc)), 50.60
(C(30)), 54.93 (2  O-CH3(DMT)), 62.72 (C(50)), 65.71 (OCH2(Fmoc)),
72.60 (C(20)), 80.82 (C(40)), 85.55, 89.62 (C(10), 113.10, 119.75,
120.08, 125.21, 126.58, 127.06, 127.60, 127.68, 127.74, 129.62,
129.73, 135.35, 135.46, 137.68 (C(2) or C(8)), 140.6939, 143.80,
144.75, 149.72 (C(ar)), 151.93 (C(2) or C(8)), 154.26, 156.42,
157.96, 158.00, 169.22 ppm.
4.1.9. 30-{[N-(9-Fluorenyl)methoxycarbonyl-glycyl]amino}-30-
deoxy-50-O-(4,40-dimethoxytrityl)-N6,N6-dimethyl-20-O-[1,6-
dioxo-6-(pentaﬂuorophenyloxy)hexyl]-b-D-adenosine (7)
Compound 6 (289 mg, 0.331 mmol), 4-(dimethylamino)pyri-
dine (40 mg, 0.331 mmol) and bis(pentaﬂuorophenyl) adipate
(506 mg, 1.06 mmol) were dried over phosphorus pentoxide
under high vacuum for 30 min. Dry pyridine and dry DMF
(5 mL each) was added and the solution was stirred for 4 h at
room temperature, after which the starting material was no
longer visible on TLC. All volatiles were evaporated under high
vacuum and compound 7 was puriﬁed by silica gel column chro-
matography with 0–30% acetone in dichloromethane. Yield:
198 mg white foam (51%). TLC (25% acetone in dichloromethane):
Rf = 0.41. 1H NMR (300 MHz, DMSO-d6): d 1.62 (br s, 4H, 2  CH2
(adipate)), 2.75 (m, 2H, CH2(adipate)), 3.21 (m, 2H, HC(50)), 3.46
(br s, 6H, C(6)-N(CH3)2), 3.65 (m, 2H, CH2(a, Gly)), 3.70 (s,
2  O-CH3(DMT)), 4.21–4.29 (m, 4H, H-C(40), H-C(9, Fmoc),
OCH2(Fmoc)), 5.09 (m, 1H, H-C(30)), 5.83–5.87 (m, 2H, H-C(20)),
6.20 (d, J = 3.1 Hz, 1H, H-C(10)), 6.78–6.82 (m, 4H, H-C(ar)),
7.17–7.41 (m, 14H, H-C(ar)), 7.56 (t, J = 6.1 Hz, 1H, NH(Gly)),
7.69 (d, J = 7.2 Hz, 2H, H-C(ar)), 7.87 (d, J = , 7.3 Hz, 2H, H-C(ar)),
8.17 (m, 1H, NH(C30)), 8.20 (s, 1H, H-C(2) or H-C(8)), 8.28 (s,1H, H-C(2) or H-C(8)) ppm. ESI-MS (m/z): [M+Na]+ calcd for
C62H56F5N7O11, 1192.39; found 1192.30.
4.1.10. DMTO-m62A-30-NH-(Fmoc-Gly) solid support (8)
Active ester 7 (187 mg, 0.160 mmol) and amino-functionalized
support (GE Healthcare, Custom Primer Support™ 200 Amino,
560 mg) were weighed into a 10 mL ﬂask and dried under high vac-
uum. The ﬂask was ﬂushed with argon and equipped with a rubber
septum. Dry pyridine (26 lL, 0.320 mmol) and dry DMF (3.5 mL)
were added and the reaction vessel was agitated for one day. The
solid support was ﬁltered and washed with DMF, methanol and
dichloromethane (twice 10 mL each) and dried. The beads were
capped with a mixture of 10 mL 0.2 M phenoxyacetic anhydride
in dry THF and 10 mL of 0.2 M 1-methyl imidazole and 0.2 M
2,4,6-trimethylpyridine in dry THF for 10 min at room temperature.
The suspension was ﬁltered and the support was washed with ace-
tonitrile, methanol, and dichloromethane (50 mL each) and dried
under vacuum. The very ﬁrst ﬁltrate, containing residual active
ester 7, was used to treat another 400 mg of amino-functionalized
support for 3.5 days. Loading of the ﬁrst batch of support 8 was
45 lmol/g; loading of the second batch was 71 lmol/g.
4.1.11. 30-{[N-(9-Fluorenyl)-methoxycarbonyl-N6,N6,N6-
(trimethyl)-L-lysyl]amino}-30-deoxy-50-O-(4,40-
dimethoxytrityl)-N6,N6-dimethyl-b-D-adenosine (9)
Fmoc protected N6,N6,N6-trimethyl-L-lysine chloride (90 mg,
0.20 mmol), HBTU (64 mg, 0.17 mmol), HOBt monohydrate
(26 mg, 0.17 mmol) and N,N-diisopropylethylamine (35 lL,
0.20 mmol) were dissolved in 3.0 mL of DMF. After 5 min com-
pound 5a (78 mg, 0.13 mmol) was added and the solution stirred
for 12 h. All volatiles were evaporated and the residue partitioned
between 50 mL of dichloromethane and 5% aqueous citric acid. The
organic layer was washed with saturated sodium bicarbonate solu-
tion and brine (50 mL each). Due to perseverant emulsions, the
aqueous phases were re-extracted with 30 mL of dichloromethane.
The organic phases were combined and dried over molecular
sieves. After evaporation of the solvent, a yellow foam was
obtained. The crude product was puriﬁed by silica gel column
chromatography using a gradient from 5% to 10% methanol in
dichloromethane. Yield: 36 mg (27% calculated as chloride salt)
of compound 9 as a greyish solid. TLC (10% methanol in dichloro-
methane): Rf = 0.10. 1H NMR (300 MHz, DMSO-d6): d 1.24 (m, 2H,
CH2(c, Lys)), 1.50–1.63 (m, 4H, CH2(b, Lys), CH2(d, Lys)), 3.02 (s,
9H, (CH3)3N+), 3.16–3.25 (m, 4H, H(a)-C(50), H(b)-C(50), CH2(e,
Lys)), 3.45 (br s, 6H, C(6)-N(CH3)2), 3.72 (s, 6H, 2  O-CH3(DMT)),
4.12–4.33 (m, 5H, H-C(40), H-C(9, Fmoc), OCH2(Fmoc), CH(a,
Lys)), 4.66 (m, 1H, H-C(20)), 4.72–7.79 (m, 1H, H-C(30)), 6.03 (m,
1H, HO-C(20)), 6.18 (d, J = 4.5 Hz, 1H, H-C(10)), 6.79–6.83(m, 4H,
H(ar)), 7.18–7.27 (m, 7H, H(ar)), 7.30–7.44 (m, 6H, H(ar)), 7.52
(d, J = 8.5 Hz, 1H, NH(Lys)), 7.69–7.73 (m, 2H, H(ar)), 7.89 (d,
J = 7.4 Hz, 2H, H(ar)), 8.01 (d, J = 8.3 Hz, 1H, NH(C30)), 8.21 (s, 1H,
C(2) or C(8)), 8.27 (s, 1H, C(2) or C(8)) ppm. ESI-MS (m/z): [M+]
calcd for C57H65N8O8, 989.49; found 989.58.
4.1.12. DMTO-m62A-30-NH-(Fmoc-Lys(CH3)3) solid support (10)
Compound 9 (30 mg, 0.029 mmol), 4-dimethylaminopyridine
(4 mg, 0.03 mmol) and bis(pentaﬂuorophenyl) adipate (30 mg,
0.06 mmol) were dried in high vacuum for 2 h and dissolved in
1.5 mL of dry DMF and 1.0 ml of dry pyridine. After 2 h TLC indicated
complete conversion to intermediate 9a and amino-functionalized
support (GE Healthcare, Custom Primer Support™ 200 Amino,
150 mg) was added. The suspension was agitated for one day at
room temperature and then ﬁltrated. The solid support was washed
with DMF, methanol, dichloromethane (2  10 mL each) and dried
in high vacuum. Capping was performed with a mixture of 10 mL
0.2 M phenoxyacetic anhydride in dry THF and 10 mL of 0.2
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for 20 min at room temperature. The beads were ﬁltered and
washed with acetonitrile, methanol and dichloromethane (50 mL
each). The very ﬁrst ﬁltrate, containing residual active ester, was
used to treat another 100 mg of amino-functionalized support for
4 days. Loading of the ﬁrst batch of support 10 was 18 lmol/g;
loading of the second batch was 11 lmol/g.
4.2. Solid-phase peptide and oligonucleotide synthesis,
deprotection and puriﬁcation of RNA-amino acid conjugates
4.2.1. Manual solid-phase peptide synthesis on the amino acyl
charged solid support 8
The solid support 8 (4 lmol loaded conjugate) was transferred
to a fritted syringe. After each reaction step the supernatant
reagent solutions were pushed through the ﬁlter and the solid sup-
port was washed with twice 3 mL DMF. After initial soaking with
DMF, Fmoc protecting groups were removed by treating twice with
20% piperidine in DMF (1.5 mL, 8 min; 1.5 mL 12 min). Coupling
was achieved by agitation of the beads with a premixed solution
of 0.4 M Fmoc protected amino acid in 500 lL of DMF, 750 lL
activator solution in DMF (0.6 M O-(benzotriazol-1-yl)-N,N,N0,
N0-tetramethyluronium hexaﬂuorophosphate, 0.6 M 1-hydroxy-
benzotriazole) and 140 lL of N,N-diisopropylethylamine at room
temperature for one hour. This coupling step was repeated once
to ensure complete conversion. Finally, the support was washed
thoroughly with acetonitrile, dried in high vacuum and supplied
to solid-phase oligonucleotide synthesis.
4.2.2. Solid-phase oligonucleotide synthesis on the amino acyl
charged solid supports 8 and 10
All oligonucleotides were synthesized on a 1.0 lmol scale using
an Applied Biosystems ABI 392 following standard synthesis proto-
cols. Detritylation (2 min): 4% (v/v) dichloroacetic acid in 1,2-
dichloroethane. Coupling (3 min): 120 lL 0.1 M phosphoramidite
in acetonitrile plus 360 lL 0.30 M 5-(benzylthio)-1H-tetrazole in
acetonitrile as activator. Capping (2  0.5 min): 1:1 (v/v) Cap A/
Cap B, Cap A: 0.2 M phenoxyacetic anhydride in dry THF, Cap B:
0.2 M 1-methyl imidazole and 0.2 M 2,4,6-trimethylpyridine in
dry THF. Oxidation (1 min): 20 mM iodine in 7/2/1 (v/v/v) THF /
pyridine / water. Phosphoramidite and activator solutions were
dried over activated molecular sieves (3 Å) overnight. All
sequences were synthesized trityl-off.
4.2.3. Deprotection of RNA-amino acid conjugates
The solid support was treated with 20 mL of 12% (v/v) diethyl-
amine in acetonitrile over 15 min, washed with 20 mL of acetoni-
trile and dried in high vacuum. The beads were transferred into a
screw-capped Eppendorf tube and 1.5 mL of a 3:1 mixture of 30%
aqueous ammonia and ethanol was added and the reaction pro-
ceeded at 45 C for 4 h with occasional shaking. The suspension
was ﬁltered and all volatiles evaporated. The residue was dissolved
in 1.3 mL of 1 M tetrabutylammonium ﬂuoride trihydrate in THF
and kept at 37 C for 12 h. The reaction was quenched by addition
of 1.3 mL of triethylammonium bicarbonate buffer (1 M, pH 7.4)
and the organic solvent evaporated. The solution was diluted with
triethylammonium bicarbonate buffer (100 mM, pH 7.4) to
approximately 2 mL, applied onto an equilibrated C18 SepPakPlus
cartridge (Waters), washed with water and the aminoacylated RNA
eluted with water/acetonitrile (1/1, v/v). The dried crude product
was redissolved in 1.0 mL of water.
4.2.4. Analysis and puriﬁcation of RNA-amino acid conjugates
Analysis of crude products was performed by anion-exchange
HPLC on a Dionex DNAPacPA-100 column (4  250 mm) at
60 C. Flow rate: 1 mL/min; eluant A: 25 mM TrisHCl (pH 8.0),6 M urea; eluant B: 25 mM TrisHCl (pH 8.0), 6 M urea, 500 mM
NaClO4; gradient: 0–40% B in A within 25 min; UV-detection at
260 nm. Crude products were puriﬁed on a semi-preparative
Dionex DNAPacPA-100 column (9x250 mm) at 60 C. Flow rate:
2 mL/min; gradient: 3–10% B in A within 18 min for tetranucleo-
tides, 13–23% B in A within 18 min for hexanucleotides; UV-
detection at 260 nm. Fractions containing the oligonucleotide were
diluted with en equal volume of triethylammonium bicarbonate
buffer (100 mM, pH 7.4) and loaded on an equilibrated C18
SepPakPlus cartridge (Waters), washed with water and eluted
with water/acetonitrile (1/1, v/v). Puriﬁed fractions were
evaporated and redissolved in 1.0 mL water. The RNA yield was
determined as units of optical density at 260 nm by UV spectros-
copy (Implen NanoPhotometer) at room temperature. The product
quality and purity was veriﬁed by anion-exchange chromatogra-
phy on an analytical column (vide supra).
4.2.5. LC-ESI mass spectrometry of RNA-peptide conjugates
All analyses were performed on a Finnigan LCQ Advantage MAX
ion trap instrumentation (Thermo Fisher Scientiﬁc) connected to an
Amersham Ettan micro LC system (GE Healthcare). RNA-amino acid
conjugates were analyzed in the negative-ion mode with a poten-
tial of 4 kV applied to the spray needle. LC: sample: 200 pmol
lyophilized conjugate dissolved in 30 lL. Column: XTerraMS,
C18 2.5 lm, 1.0  50 mm at 21 C; ﬂow rate: 30 lL/min; eluant
A: 8.6 mM triethylamine, 100 mM 1,1,1,3,3,3-hexaﬂuoroisopropa-
nol in water (pH 8.0); eluant B: methanol; gradient: 0–100% B in
A within 20 min; UV-detection at 254 nm. Prior each injection,
column equilibration was performed by eluting buffer A for
30 min at a ﬂow rate of 30 lL/min.
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